In the News/New Products
SynergEyes Modification to Multifocal Lens
On May 20, 2010 SynergEyes, the high Dk hybrid contact lens manufacturer, has introduced a slight modification to the SynergEyesMultifocal lens, designed to enhance comfort and wearability for patients with normal corneas. The modification known as the Peripheral Blend is now available in all lens parameters. The Peripheral Blend modification slightly flattens the lens at the RGP periphery and the soft skirt to create a less pronounced landing zone across a broader area of the peripheral cornea. SynergEyes suggests that patients with small corneas, corneas with high eccentricity values, and any patient experiencing discomfort, tightness, or removal issues when all other parameters are optimized will benefit from the Peripheral Blend modification.
B and L Introduces New Soothe Xtra Hydration Lubricant Eye Drops
Early in May, Bausch and Lomb announced the U.S. launch of new Soothe Xtra Hydration lubricant eye drops. The Soothe portfolio is now aligned with the most recent international Dry Eye Workshop (DEWS) sponsored by the Tear Film & Ocular Surface Society.
DEWS created a new definition of dry eye and helped develop two major classifications of dry eye—aqueous-deficient dry eye and evaporative dry eye. New Soothe Xtra Hydration, for aqueous-deficient dry eye therapy, moisturizes and restores the deficient aqueous and mucin layers of the tear film to provide lasting hydration and comfort. Soothe XP Xtra Protection, for evaporative dry eye therapy, reestablishes the lipid layer of the tear film to provide up to 8 hours of relief.
Sirion Therapeutics Announces Zirgan for Ocular Herpes: B & L Obtains Assets and U.S. Rights
Late in April, Sirion Therapeutics, announced that Zirgan (ganciclovir ophthalmic gel) 0.15% is now commercially available. Zirgan, which was approved by the U.S. Food and Drug Administration in September 2009, is a topical ophthalmic antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers). Sirion reports that herpetic keratitis is the number one infectious cause of corneal blindness in the U.S. Zirgan has been a leading treatment for corneal ulcers, under the brand name Virgan, in Europe for more than 10 years. On June 3, 2010, Bausch & Lomb announced that it had acquired the assets and U.S. rights for Zirgan® (ganciclovir ophthalmic gel 0.15%) from Sirion Therapeutics, Inc.
Haag-Streit Introduces LED Slit Lamp: The BQ 900
Early in May, Haag-Streit USA introduced the BQ 900, that they note is “the first LED powered slit lamp.” LED illumination is said to deliver improved anterior and posterior viewing compared to other light sources, with the brightest slit for more detailed viewing. The FDA approved the new slit lamp in February 2010.
Haag-Streit calls the BQ 900 its sharpest, most even illuminating slit lamp to date. They report that the LED light is more homogeneous and provides clearer viewing than traditional, tungsten bulbs, and that it “doesn’t yellow as the bulb ages and the light quality isn’t affected by power surges like tungsten bulbs are.” Beyond the improved visibility, the LED bulbs are said to “last a lifetime.”
Eye Supplement Program to Manage AMD Risk Factor
Eye-Q is intended to be an AMD Risk Management program for EyeCare Professionals and patients to manage a key risk factor for age-related macular degeneration (AMD). The program allows EyeCare Professionals to measure, manage, monitor, and maintain healthy macular pigment. They note that low macular pigment is a critical risk factor for AMD. Eye-Q includes a measurement device that measures macular pigment level. With low macular pigment, EyeCare Professionals may prescribe EyePromise Restore, a supplement that contains a variety of nutrients including Zeaxanthin and Lutein—two carotenoids found in the macula. Eye-Q describes macular pigment as acting as a protective film or “internal sunglasses” to protect the eye from harmful blue light and oxidative stress.